All reports
Pharmaceutical
Obesity & Metabolic
GLP-1 Agonists Market: Novo Nordisk vs Eli Lilly
Code: NSC/PHRM/0002Published Mar 15, 2026Data window: 6 months
About this report
Market growing from $64B (2025) to $170B (2033). Wegovy/Ozempic vs Mounjaro/Zepbound, capacity, payer contracts.
Humans at the core of the analysis
Partner specialist firms, independent domain experts and our in-house analyst team: every report is written and reviewed by humans who cross-check signals, verify sources and prioritise what matters.
Key insights
Request the sample to discover the report's key insights.
Table of contents
The detailed table of contents is shared with the free sample.